Skip to main content
Premium Trial:

Request an Annual Quote

Upstream Will Use Genpathway's ChIP Assays to Validate Cancer Biomarkers

NEW YORK (GenomeWeb News) — Upstream Biosciences has hired Genpathway to use its chromatin immunoprecipitation assays in its cancer biomarker-validation studies, Upstream Bio said today.
 
Genpathway will use its assays to “help elucidate critical parameters involving specific gene transcription factors and pathways” and provide “critical information for the next phase of Upstream's program to validate its first two cancer biomarkers and drug response assay,” according to Upstream.
 
Upstream said the regulatory regions involve gene switches that control conditions related to gene activation, the number of copies of the gene produced, and variations in these regions that have been linked to cancer.  
 
The company said it has five provisional patent filings for these variations as cancer biomarkers that may help to help early cancer detection.
 
Upstream CEO Joel Bellenson said the agreement “builds on the important analytic work we already have underway with NimbleGen and may allow us to acquire in-depth information that is not available with other analytic methods."
 
Financial terms of the agreement were not released.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.